Valentina Piastra
Research Subjects
Valentina Piastra has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Angelina Pranteda
Oncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCCS—Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
1 shared publication - Deborah Fratantonio
Department of Medicine and Surgery, LUM University, S.S. 100 Km 18, 70100 Casamassima, Italy
1 shared publication - Gianluca Bossi
Laboratory of Medical Physics and Expert Systems, Regina Elena National Cancer Institute, Rome, Italy
1 shared publication - Lorenzo Stramucci
Oncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCCS—Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 16 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2773
The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents. In the case of rectal carcinoma, radiation therapy also represents a therapeutic strategy. In an attempt at translating much-needed new targeted therapy to the clinics, p38 mitogen activated protein kinase (MAPK) inhibitors have been tested in clinical trials involving colorectal carcinoma patients, especially in combination with chemotherapy; however, despite the high expectations raised by a clear involvement of the p38 MAPK pathway in the response to therapeutic treatments, poor results have been obtained so far. In this work, we review recent insights into the exact role of the p38 MAPK pathway in response to currently available therapies for colorectal carcinoma, depicting an intricate scenario in which the p38 MAPK node presents many opportunities, as well as many challenges, for its perspective exploitation for clinical purposes.
- 16 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2773
Open AccessThe p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents. In the case of rectal carcinoma, radiation therapy also represents a therapeutic strategy. In an attempt at translating much-needed new targeted therapy to the clinics, p38 mitogen activated protein kinase (MAPK) inhibitors have been tested in clinical trials involving colorectal carcinoma patients, especially in combination with chemotherapy; however, despite the high expectations raised by a clear involvement of the p38 MAPK pathway in the response to therapeutic treatments, poor results have been obtained so far. In this work, we review recent insights into the exact role of the p38 MAPK pathway in response to currently available therapies for colorectal carcinoma, depicting an intricate scenario in which the p38 MAPK node presents many opportunities, as well as many challenges, for its perspective exploitation for clinical purposes.